Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Dabigatran etexilate, a direct thrombin inhibitor, is one of a new class of oral anticoagulants that was recently demonstrated in a Phase 3 trial to be effective for the prevention of stroke or systemic embolism (SSE) in patients with atrial fibrillation (AF).

Long-Term Results of Dabigatran vs Warfarin for Stroke Prevention in AF Patients